Details
Stereochemistry | ACHIRAL |
Molecular Formula | Ca.HO4P |
Molecular Weight | 136.057 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].OP([O-])([O-])=O
InChI
InChIKey=FUFJGUQYACFECW-UHFFFAOYSA-L
InChI=1S/Ca.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+2;/p-2
DescriptionSources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlCurator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details
Sources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.html
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details
Anhydrous dibasic calcium phosphate is a calcium salt of phosphoric acid. It is used as a diluent in pharmaceutical industry, in some toothpastes as a polishing agent. Calcium phosphate is generally recognized as safe by FDA. Dibasic calcium phosphate is ised as a supplement to treat conditions associated with calcium deficit, such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany)
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseHypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
Title | Date | PubMed |
---|---|---|
1,25 dihydroxyvitamin D3 enhances the calcium response of keratinocytes. | 1999 Feb |
|
Aluminum is a weak agonist for the calcium-sensing receptor. | 1999 May |
|
Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity. | 1999 Sep 20 |
|
Effect of ADP and ionic strength on the kinetic and motile properties of recombinant mouse myosin V. | 2000 Feb 11 |
|
Hepatocyte growth factor disrupts cell contact and stimulates an increase in type 3 inositol triphosphate receptor expression, intracellular calcium levels, and apoptosis of rat ovarian surface epithelial cells. | 2000 Jun |
|
Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement. | 2000 Oct 15 |
|
Chemokines induce eosinophil degranulation through CCR-3. | 2000 Sep |
|
Pilocarpine-induced status epilepticus causes N-methyl-D-aspartate receptor-dependent inhibition of microsomal Mg(2+)/Ca(2+) ATPase-mediated Ca(2+) uptake. | 2000 Sep |
|
Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells. | 2001 Aug |
|
Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine. | 2001 Jul |
|
Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. | 2001 Mar 15 |
|
Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes. | 2001 Mar 2 |
|
RGS4 inhibits platelet-activating factor receptor phosphorylation and cellular responses. | 2001 Mar 27 |
|
Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors. | 2001 Nov 1 |
|
Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. | 2001 Nov 30 |
|
Familial intrahepatic cholestasis 1: studies of localization and function. | 2001 Oct |
|
Microarray analysis of differential gene expression in lead-exposed astrocytes. | 2001 Oct 1 |
|
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002 May 15 |
|
A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs. | 2002 Sep 6 |
|
Henri Moissan: winner of the Nobel Prize for Chemistry 1906. | 2006 Oct 20 |
|
Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial. | 2015 Aug 12 |
|
Lactose behaviour in the presence of lactic acid and calcium. | 2016 Aug |
Sample Use Guides
oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid).
inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CODEX ALIMENTARIUS (GSFA) |
INS-341(II)
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
||
|
JECFA EVALUATION |
INS-341(II)
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
24441
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | |||
|
47627
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | |||
|
100000087353
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | |||
|
L11K75P92J
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | |||
|
DICALCIUM PHOSPHATE
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | |||
|
ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | Description: A white or almost white powder; odourless. Solubility: Practically insoluble in cold water and ethanol (~750 g/l) TS; soluble in dilute acids. Category: Tablet and capsule diluent. Storage: Calcium hydrogen phosphate should be kept in a well-closed container. Labelling: The designation on the container of Calcium hydrogen phosphate should state whether it is the dihydrate or the anhydrous form. Requirement: Calcium hydrogen phosphate contains not less than 30.9% and not more than the equivalent of 31.7% of calcium, Ca, calculated with reference to the ignited substance. | ||
|
L11K75P92J
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | |||
|
DBSALT002430
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | |||
|
32596
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | |||
|
4496
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | |||
|
C77523
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | |||
|
m2964
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL2107567
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | |||
|
231-826-1
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | |||
|
992
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | |||
|
DTXSID20872529
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | |||
|
C1505
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
CONCEPT | Dietary Supplement | ||
|
SUB16368MIG
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | |||
|
253163
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
ALTERNATIVE | |||
|
SUB11772MIG
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY | |||
|
7757-93-9
Created by
admin on Fri Dec 15 15:30:58 GMT 2023 , Edited by admin on Fri Dec 15 15:30:58 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
ACTIVE MOIETY